NCT00691808View on ClinicalTrials.gov

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2008

Conditions
Age-Related Memory Disorders
Interventions
DRUG

LX6171 High Dose

A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

DRUG

LX6171 Low Dose

A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.

DRUG

Placebo

Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.

Trial Locations (2)

3584

Kendle Netherlands, Utrecht

9470

Pharmaceutical Research Associates Group BV, Zuidlaren

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY